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Abstract
Background: Brucellosis is one of the most common zoonotic disease affecting humans and animals and is endemic
in many parts of the world including the Gulf Cooperation Council region (GCC). The aim of this study was to identify
the species and determine the antimicrobial susceptibility pattern of Brucella strains isolated from clinical specimens,
from Qatar.
Results: We evaluated 231 Brucella isolates. All isolates were identified as B. melitensis. All the isolates were susceptible
to doxycycline, tetracycline, streptomycin, gentamicin, trimethoprim / sulfamethoxazole and ciprofloxacin except
rifampicin, where 48 % of the strains showed elevated MICs (>1 mg/L). The rifampicin-resistance related hotspots
within the rpoB gene were amplified and sequenced using PCR and no rpoB mutations were found in strains with
rifampicin MICs of >2 mg/L.
Conclusion: This study identified B. melitensis as the etiological agent of brucellosis in Qatar. No resistant isolates
were detected among conventionally used antimicrobial agents.
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Background
Brucellosis is a worldwide zoonotic disease in both ani-
mals and humans with an estimated 500,000 new cases
annually [1]. Although brucellosis is a notifiable disease in
many countries, it is probably underreported and official
numbers do not reflect the true incidence of this infection
[2]. Thus the true incidence of human brucellosis is un-
known and the estimated burden of the disease varies
widely, from < 0.03 to >160 per 100,000 population. The
highest recorded incidence of human brucellosis occurs in
the Middle East and Central Asia [3]. Brucellosis is trans-
mitted to humans by direct contact with infected animals
or consumption of unpasteurized or inadequately cooked
milk or milk products, inhalation of infected aerosolized
particles and, to a lesser extent, meat derived from cattle,
sheep, goats, pigs, camels, yaks, buffaloes or dogs. Four
species of the genus Brucella are usually pathogenic for
humans, which include B. melitensis (from sheep/goats
and camel), B. abortus (from cattle and other bovine
animals), B. suis (from pigs), and B. canis (from dogs)
[4]. Routine susceptibility testing of Brucella species is
not performed due to the need for containment level 3
facilities [4] and concerns of laboratory-acquired infec-
tions [5]. The main objective of this study was to deter-
mine the antimicrobial susceptibility pattern of human
Brucella isolates from patients in Qatar collected over a
10 -year period.
Methods
Bacterial isolates
A total of 231 strains of Brucella isolates obtained from
various clinical specimens (blood n = 225 and synovial
fluid n = 6) collected between January 2005 and July
2014 from patients attending Hamad General Hospital
and Al Khor Hospital, Qatar, were included in the study.
All the isolates were collected as a part of standard pa-
tient care. Identification of isolates was based on colony
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morphology, Gram stain, oxidase, catalase, Vitek 2 com-
pact (bioMerieux, Durham, USA) and Maldi-TOF MS
(Bruker Daltonics, Bremen, Germany). For Maldi-TOF
MS, cultures were processed using the ethanol/formic
acid/acetonitrile protocol [6]. All cultures were proc-
essed in a Class II biological safety cabinet in a negative
pressure room.
Antimicrobial susceptibility testing
Susceptibility of seven antibiotics (doxycycline, tetracyc-
line, streptomycin, gentamicin, rifampicin, trimethoprim/
sulfamethoxazole and ciprofloxacin) was determined with
a gradient strip method (E-test strips, bioMerieux, Marcy
L’Etoile, France). The antimicrobial strips were placed on
Muller Hinton blood agar according to the manufacturer’s
guidelines and read after 48 h incubation in ambient air at
37 °C. Minimum inhibitory concentrations (MIC) break-
points of streptomycin, gentamicin, tetracycline, doxycyc-
line and trimethoprim-sulfamethoxazole were used as
recommended by CLSI [7]. As MIC breakpoints for
Brucella against rifampicin and ciprofloxacin have not
been established, guidelines for slow-growing bacteria
(H.influenzae) were used [8, 9]. The MIC was interpreted
as the value at which the inhibition zone intercepted the
scale on the E-test strip and the MIC values were rounded
up (to the next higher dilution) with the corresponding
MIC of the microbroth dilution method. MIC50 and
MIC90 levels were defined as the lowest concentration of
the antibiotic at which 50 % and 90 % of the isolates
were inhibited, respectively.
The reference strains- H. influenza ATCC 10211, E.coli
ATCC 25922, S.pneumoniae ATCC 49619 and S.aureus
ATCC 29213 were used as quality control.
PCR assay of rpoB gene
For isolates (n = 17) that showed a rifampicin MIC of >
2 mg/L, the rifampicin-resistance related hotspots within
the rpoB gene were amplified and sequenced as de-
scribed before [10]. The sequences were compared to
rpoB sequences of wildtype and resistant isolates as pro-
vided by other studies [10, 11].
Results
All the isolates were identified by Vitek II compact and
Maldi-TOF as B. melitensis. Table 1 represents MIC
range; MIC50 and MIC90 of each antibiotic tested and
MIC distributions are shown in Fig. 1.
All the isolates were susceptible to doxycycline (MIC90,
0.25 mg/L), gentamicin (MIC90, 0.5 mg/L), streptomycin
(MIC90, 2 mg/L), trimethoprim-sulfamethoxazole (MIC90,
0.25 mg/L) and tetracycline (MIC90, 0.25 mg/L). In
addition, ciprofloxacin (MIC90, 0.5 mg/L) showed 100 %
susceptibility when MIC breakpoint criteria for H.influen-
zae [8] were used. For rifampicin, the MIC values ranged
from 0.008 to 4 mg/L and when compared with MIC
breakpoint criteria for H.influenzae [8], resistance (MIC ≥
2 mg/L) was demonstrated in 48 % strains. After sequen-
cing of the rpoB gene, no mutations were found in isolates
with MIC of > 2 mg/L (n = 17).
Discussion
Brucella melitensis is the commonest etiological agent
causing human brucellosis worldwide. Intracellular
localization of Brucella species within monocytes and
macrophages of the reticulo-endothelial system limits
the choices of antimicrobial agents for effective treat-
ment of systemic and localized brucellosis. Although a
variety of antimicrobial agents appear to be active
in vitro, the results of susceptibility testing do not always
correlate with clinical efficacy [4].
The recommended method for antimicrobial suscepti-
bility testing of Brucella species is microbroth dilution
using unsupplemented Brucella broth [7]. When the E-
test method was compared with microbroth dilution,
Gur et al. found no significant variations in obtained
MIC values [12]. This method appear to be reliable, re-
producible, easily performed, and produces similar re-
sults to those of conventional methods for Brucella on
Muller Hinton blood agar [13, 14] and it is therefore
that we used E-test for susceptibility testing.
Amongst tetracyclines, doxycycline is the most com-
mon antimicrobial drug used for treatment of uncom-
plicated brucellosis in adults and children of more than
8 years [4]. In the present study, MICs of tetracycline
Table 1 Antimicrobial susceptibility of B.melitensis
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) Breakpoints for susceptibility (mg/L)
Doxycycline 0.032–1 0.125 0.25 ≤1 [7]
Tetracycline 0.032–0.5 0.125 0.25 ≤ 1 [7]
Gentamicin 0.064–2 0.25 0.5 ≤ 4 [7]
Streptomycin 0.125–4 0.5 2 ≤ 8 [7]
Trimethoprim-Sulfamethoxazole 0.008–2 0.064 0.25 ≤ 2/38 [7]
Rifampicin 0.008–4 1 2 ≤ 1 [8]
Ciprofloxacin 0.064–0.5 0.25 0.5 ≤ 1 [8]
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(range - 0.032–0.5 mg/L) and doxycycline (range - 0.032–
1 mg/L) are found to be in the susceptible category and
MIC50 and MIC90 values are consistent with previous re-
ports [9, 13, 15, 16]. However, increased MICs of doxycyc-
line have been reported in a study from Mexico [17].
The World Health Organization (WHO) recommends
doxycycline (6 weeks) in combination with aminoglyco-
sides (streptomycin or gentamicin for 2–3 weeks) or ri-
fampicin (6 weeks) [4]. The most preferred and effective
aminoglycoside in treatment of brucellosis is strepto-
mycin [4, 18, 19]. Combination with streptomycin was
found to be superior as compared to rifampicin, in terms
of relapse or treatment failure [18]. Even though genta-
micin is more active in vitro and is associated with fewer
side effects than streptomycin, there are not enough
studies, which justify the replacement of streptomycin
[4, 19]. In the present study, all the strains were suscep-
tible to streptomycin (0.125–4 mg/L) and gentamicin
(0.064–2 mg/L) and found to be in the range described
previously [9, 15]. Nevertheless, a high MIC90 of strepto-
mycin (8 mg/L) was reported from Turkey [16].
Another commonly used drug in treatment of brucel-
losis in combination with doxycycline is rifampicin. In
spite of the proven efficacy with aminoglycoside combin-
ation, due to the need for parenteral administration,
convenience and poor patient compliance, healthcare
professionals prefer the all-oral regimen of doxycycline/
rifampicin [18, 20]. A meta-analysis on various combina-
tions used for the treatment of brucellosis, has shown
higher relapse rate with doxycycline/rifampicin when com-
pared to doxycycline/streptomycin regimen [21]. It has
been suggested that rifampicin may enhance the plasma
clearance of doxycycline resulting in lower doxycyline levels
[22] and the possibility that its use could contribute to
emergence of rifampicin- resistant Mycobacterium tubercu-
losis in endemic countries [23]. For in-vitro susceptibility
testing, MIC breakpoints of rifampicin against Brucella has
not been established and therefore these organisms cannot
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Fig. 1 Distribution of MIC values in indicated antimicrobials of B. melitensis from Qatar
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be confidently characterised as susceptible, intermediate or
resistant. However, when compared with CLSI reference
values for H.influenzae [8], in the present study, 48 % of
Brucella strains showed elevated MIC’s of rifampicin
(>1 mg/L). Higher MIC’s to rifampicin has been reported
previously from Egypt (64 %) [9] and Malaysia (70 %) [15].
However, the impact of high MIC’s on clinical outcome in
these countries is not known. In Qatar, in a retrospective
cohort study, combination of doxycyline with streptomycin
was found to be the preferred regimen followed by doxycy-
line with rifampicin and no relapse or therapeutic failures
were detected [24].
Mutations conferring rifampin resistance are confined
almost exclusively to the rpoB gene in most organisms
and result in a decreased affinity of the DNA-dependent
RNA polymerase to the antibiotic. Alternative mecha-
nisms of rifampin resistance also have been observed
[25]. Along with mutations in the rpoB gene, excitation
of several metabolic processes may also be a contribut-
ing factor in conferring rifampicin resistant in Brucella
[26]. We did not find any mutations in the rpoB gene in
isolates with elevated MIC’s in this study, findings consist-
ent with previous studies [14, 27, 11]. However, further re-
search is required to find possible other mechanisms of
rifampicin resistance in Brucella.
Trimethoprim/sulfamethoxazole (TMP/SMX) is an al-
ternative agent recommended for treatment of brucel-
losis in pregnancy and in children under 8 years old. It
has also been recommended for treatment of osteo-
articular complications, neurobrucellosis and endocardi-
tis, in combination with doxycycline, aminoglycoside
and rifampicin [4]. TMP/SMX, when used in combin-
ation with rifampicin, was found to be effective in
pediatric patients (8 weeks regimen). High relapse rates
were noted when TMP/SMX was used as a monotherapy
in pediatric brucellosis [28]. Development of resistance
to TMP/SMX to B. melitensis is an important issue.
High rate of resistance to TMP/SMX has been reported
from previous studies [17, 29]. In the present study,
TMP/SMX was found to be susceptible with low MIC50
(0.064 mg/L) and MIC90 (0.25 mg/L) when compared to
other antimicrobials which is consistent with previous
reports [9, 13, 15].
Ciprofloxacin is a potential alternative therapeutic op-
tion in the treatment of brucellosis with excellent oral
bioavailability and reaching high concentrations in
phagocytic cells [30]. However, ciprofloxacin is not rec-
ommended for monotherapy due to the lack of bacteri-
cidal activity at the intracellular acidic pH [31], high rate
of relapse and the risk of development of overall fluoro-
quinolone resistance in the community [32]. Therefore,
its use in combination with doxycycline is recommended
as an acceptable alternative but not as first line regimen
[29, 33]. We found ciprofloxacin MICs (0.064–0.5 mg/L)
in the susceptible range when compared to MIC break-
point criteria of slow growing bacteria and these findings
are consistent with previous studies [9, 16]. Ciprofloxa-
cin based therapy might play a role as an alternative
regimen especially in patients with intolerance to com-
monly used drugs and relapsed disease [30].
Conclusion
In summary, this study identified B. melitensis as the
etiological agent of brucellosis in Qatar. No resistant iso-
lates were detected among conventional antimicrobial
agents. Periodic monitoring of antimicrobial resistance
in the Middle East, especially in the Gulf Cooperating
Council (GCC) in light of the emerging resistance and
development of CLSI or EUCAST interpretive criteria
for rifampicin are needed.
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